Parana Copper Corp. (CSE:COPR) (OTC:PNNRF) (Frankfurt:O3X4) (the “Company”) introduces Biolog, Inc. (“Biolog”) a patented cannabis infusion technology for food and beverage, as the newest client of the merchant bank, Redfund Capital Corp.

Biolog has developed a patented system to infuse virtually any food or beverage with cannabis. Their infusion process is easy and accurate, while providing significantly enhanced bioavailability and reduced onset times. The Biolog products are powered by Lexaria Bioscience Corporation’s (CSE: LXX) (OTCQX: LXRP) DehydraTECHTM technology, under a license agreement announced earlier this year by Lexaria.


The Biolog technology is protected by multiple patents and trade secrets, including a patent portfolio licensed from Lexaria, which enable consumers and processors to easily and precisely dose almost any food or beverage with either CDB, THC or any combination of these or other cannabinoids. Furthermore, (CBD) edibles manufactured with Biolog’s technology will offer improvements in bioavailability of up to 500%, while also reducing onset times for psychoactive effects from Tetrahydrocannabinol (THC) to as fast as 15 to 20 minutes.

“Redfund Capital is specifically focused on funding cannabis-related companies that have strong growth potential and that is exactly what we see in Biolog” commented Meris Kott, CEO of Redfund Capital. “Biolog’s products were specifically designed to solve the inconsistencies within the edible cannabis market and we are pleased to welcome them to the Redfund portfolio of companies.”

Bruce Bauer, CEO of Biolog, commented, “The financing from Redfund will allow us to accelerate our product schedule. The patented process we deploy allows us to produce products that normal consumers or professional processors can utilize to turn virtually any food into a cannabis edible that is accurately dosed with highly bioavailable cannabinoids. While we will enter the marketplace with a strong patent portfolio, our internally developed testing regime, which is based on some of the most advance laboratory equipment in the market, will ensure that consumers and processors can use our products with confidence.”

As previously released, Parana Copper Corp. has been informed that following the CSE’s review of the Company’s application in respect to its previously announced name change to Redfund Capital Corp. in conjunction with a change of business, the CSE has approved the Company’s proposed change of business. A date for the resumption of trading will be determined upon confirmation of the completion of a private placement, as well as completion of the usual application documentation and fees pursuant to CSE policies.

For additional information:

Email to info@paranacoppercorp.com or info@redfundcapital.com

Phone: 604-484-8989

Certain statements contained in this release may constitute “forward–looking statements” or “forward-looking information” (collectively “forward-looking
information”) as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or
future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “anticipates” and similar expressions and
statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or
assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking
information relating to the business of the Company, the Property, financing and certain corporate changes. The forward-looking information contained in this
release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new
information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein,
investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained
herein

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities
Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source: sedar.com

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less

Aphria Inc. (” Aphria “, ” we ” or the ” Company “) (TSX: APHA) (NASDAQ: APHA), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, announced it has closed the accretive, strategic acquisition (the ” Acquisition “) of  SW Brewing Company, LLC (” SweetWater Brewing Company ” or ” SweetWater “), one of the largest independent craft brewers in the United States (“U.S.”) based on volume. Beginning with the flagship 420 beverage offerings, SweetWater has created an award-winning lineup of year-round, seasonal and specialty beers, a portfolio of brands closely aligned with a cannabis lifestyle.

Keep reading... Show less
  • Distinguished economist and former CEO of Ecopetrol, Colombia’s largest corporation and the fourth largest Latin America oil and gas producer included in the Fortune Global 500
  • Internationally recognized advocate for the cannabis industry as a driver of change for the Latam economy
  • Adds proven economic and international business experience to boost the global growth of the Khiron business model
  • Company to discuss Q3 2020 financials and host webcast on Tuesday, December 1 st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announces that Mr. Juan Carlos Echeverry has been appointed to the Board of Directors of the Company, effective immediately. Mr. Echeverry brings extensive corporate, academic and macroeconomic experience, serving as Colombia’s Minister of Finance from 2010 to 2012 and as the CEO and President of Ecopetrol from 2015 to 2017.

Keep reading... Show less

 Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Aurora securities between February 13, 2020, and September 4, 2020, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/acb .

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

Keep reading... Show less